BioNTech Stock Price, News & Analysis (NASDAQ:BNTX) $99.40 -1.01 (-1.01%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$94.70▼$99.6450-Day Range$90.91▼$112.7552-Week Range$88.00▼$188.99Volume802,521 shsAverage Volume682,438 shsMarket Capitalization$23.63 billionP/E Ratio8.62Dividend YieldN/APrice Target$151.46 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.30 Rating ScoreUpside/Downside52.4% Upside$151.46 Price TargetShort InterestHealthy1.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.02Based on 17 Articles This WeekInsider TradingN/AProj. Earnings Growth-54.05%From $4.81 to $2.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector362nd out of 954 stocksBiological Products, Except Diagnostic Industry61st out of 159 stocks 3.2 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $151.46, BioNTech has a forecasted upside of 52.4% from its current price of $99.40.Amount of Analyst CoverageBioNTech has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.12% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in BioNTech has recently decreased by 18.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 3.3 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for BioNTech this week, compared to 6 articles on an average week.Search Interest33 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat FollowsOnly 73 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease by -54.05% in the coming year, from $4.81 to $2.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 8.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.76.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 8.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.27.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesDecember 1, 2023 | msn.comBioNTech Stock Downgraded, Analyst Reflects Concerns Over Growth and Pipeline DevelopmentDecember 1, 2023 | msn.comBioNTech downgraded at JPMorgan on COVID-related headwindsDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 1, 2023 | finance.yahoo.comBioNTech ADRs drop after JPMorgan lowers outlook to "underweight"December 1, 2023 | markets.businessinsider.com6 Analysts Have This to Say About BioNTechNovember 29, 2023 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Rating Reiterated by HC WainwrightNovember 28, 2023 | realmoney.thestreet.comBioNTech price target lowered to $110 from $153 at UBSNovember 21, 2023 | bizjournals.comEuropean patent office declares Moderna's Covid vaccine patent invalidDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: FibroGen (FGEN), BioNTech SE (BNTX) and Sensei Biotherapeutics (SNSE)November 7, 2023 | markets.businessinsider.comBionTech SE’s Adjusted Forecast and Future Projections: An Analysis of the Hold Rating DecisionNovember 7, 2023 | msn.comBioNTech (NASDAQ:BNTX) Rises After Q3 NumbersNovember 6, 2023 | markets.businessinsider.comCrude Oil Moves Higher; BioNTech Lowers 2023 Sales OutlookNovember 6, 2023 | markets.businessinsider.comBioNTech Q3 Profit Falls, Trims FY23 Vaccine Revenue OutlookNovember 6, 2023 | msn.comLike Moderna, BioNTech Cuts Annual Sales Forecast By 20% As Pandemic FadesNovember 6, 2023 | msn.comBioNTech Stock Surges On Surprise Profit, Strong Sales. But Drugmaker Cuts Outlook.November 6, 2023 | realmoney.thestreet.comBioNTech Gets a Shot in the Arm After Earnings: Is It Sustainable?November 6, 2023 | seekingalpha.comBioNTech Q3 Earnings Review: COVID Revenues Downgrade Makes Prognosis GloomyNovember 6, 2023 | markets.businessinsider.comBioNTech Announces Third Quarter 2023 Financial Results and Corporate UpdateNovember 6, 2023 | finance.yahoo.comBioNTech Stock Jumps On Surprise Profit, Sales BeatNovember 6, 2023 | seekingalpha.comBioNTech SE 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | markets.businessinsider.comBioNTech Receives Buy Rating Amid Anticipated Revenue Increase and Comirnaty Booster ApprovalOctober 31, 2023 | morningstar.comBioNTech SE ADR BNTXOctober 27, 2023 | markets.businessinsider.comPositive Phase 1/2 Study Results and Steady Revenue Prospects Boost BioNTech SE’s Buy RatingOctober 26, 2023 | investing.comPfizer, BioNtech say flu-COVID shot generates strong immune response in trialOctober 23, 2023 | benzinga.comBioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023October 23, 2023 | finance.yahoo.comBioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023See More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees4,530Year Founded2008Price Target and Rating Average Stock Price Target$151.46 High Stock Price Target$260.00 Low Stock Price Target$99.00 Potential Upside/Downside+52.4%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$11.53 Trailing P/E Ratio8.62 Forward P/E Ratio20.67 P/E GrowthN/ANet Income$9.94 billion Net Margins41.09% Pretax Margin52.86% Return on Equity13.15% Return on Assets11.73% Debt Debt-to-Equity Ratio0.01 Current Ratio10.38 Quick Ratio10.14 Sales & Book Value Annual Sales$18.24 billion Price / Sales1.30 Cash Flow$41.59 per share Price / Cash Flow2.39 Book Value$90.96 per share Price / Book1.09Miscellaneous Outstanding Shares237,710,000Free Float192,074,000Market Cap$23.63 billion OptionableNot Optionable Beta0.28 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesProf. Ugur Sahin M.D. (Age 58)Co-Founder, CEO & Chair of the Management Board Comp: $446kDr. Ozlem Tureci M.D. (Age 56)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $829kMr. Jens H. Holstein (Age 60)CFO & Member of Management Board Comp: $873kDr. Sierk Poetting Ph.D. (Age 50)MD, COO & Member of Management Board Comp: $917kMr. Ryan Richardson (Age 44)Chief Strategy Officer, MD & Member of Management Board Comp: $443kMr. Sean Marett (Age 58)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $850kDr. James Timothy Patrick Ryan Ph.D. (Age 48)Chief Legal Officer & Member of the Management Board Sylke Maas Ph.D.Vice President of Investor Relations and Business StrategyMichael BoehlerMD & Head of Global External CommunicationsDr. Oliver Hennig Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXModernaNASDAQ:MRNABiogenNASDAQ:BIIBNeurocrine BiosciencesNASDAQ:NBIXBio-TechneNASDAQ:TECHView All CompetitorsInstitutional OwnershipAmerican Century Companies Inc.Bought 421 shares on 11/30/2023Ownership: 0.037%Deutsche Bank AGSold 39,786 shares on 11/24/2023Ownership: 0.230%Walleye Capital LLCSold 600 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCBought 14,800 shares on 11/21/2023Ownership: 0.000%Advisors Capital Management LLCSold 1,077 shares on 11/16/2023Ownership: 0.012%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BioNTech was last updated on Tuesday, November 28, 2023 at 9:32 PM. Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech SE is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. This positions the company in a high-growth industry with significant potential for innovation and revenue growth. The company has a robust pipeline of product candidates in various stages of clinical trials. These include BNT111, BNT112, BNT113, BNT115, and BNT116, which are being tested for the treatment of advanced melanoma, prostate cancer, HPV 16+ head and neck cancers, ovarian cancer, and non-small cell lung cancer, respectively. These product candidates represent potential breakthroughs in cancer treatment and could generate substantial returns if successful. BioNTech SE has established collaborations with reputable pharmaceutical companies such as Genentech, Sanofi, Pfizer, and Genmab. These collaborations provide access to resources, expertise, and potential commercialization opportunities, which can enhance the company's chances of success and market penetration. The company is actively developing a prophylactic vaccine for various infectious diseases, including shingles, malaria, tuberculosis, and HSV-2. The global demand for vaccines has increased significantly due to the COVID-19 pandemic, and BioNTech SE's expertise in vaccine development positions it well to capitalize on this growing market. The current stock price of BioNTech SE (symbol: BNTX) reflects the market's positive sentiment towards the company's prospects. Investors who believe in the company's growth potential may see an opportunity for capital appreciation. Cons Investors should be bearish about investing in BioNTech SE for these reasons: The biotechnology industry is highly competitive and subject to regulatory uncertainties. The success of BioNTech SE's product candidates is not guaranteed, and any setbacks in clinical trials or regulatory approvals could negatively impact the company's financial performance. The company's financials may be volatile due to the nature of its business. Biotechnology companies often experience fluctuations in revenue and profitability as they progress through different stages of drug development and commercialization. Investing in clinical-stage biotechnology companies carries inherent risks. The outcomes of clinical trials are uncertain, and there is a possibility of adverse events or safety concerns arising during the testing of product candidates. The success of BioNTech SE's product candidates depends on factors such as market acceptance, pricing, reimbursement, and competition. These factors can be unpredictable and may impact the commercial viability of the company's products. Investors should carefully consider their risk tolerance and investment objectives before investing in BioNTech SE. The biotechnology sector can be volatile, and individual stock performance may deviate from broader market trends. BNTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price target for 2024? 10 equities research analysts have issued 12 month price objectives for BioNTech's stock. Their BNTX share price targets range from $99.00 to $260.00. On average, they predict the company's share price to reach $151.46 in the next year. This suggests a possible upside of 52.4% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2023? BioNTech's stock was trading at $150.22 at the start of the year. Since then, BNTX shares have decreased by 33.8% and is now trading at $99.40. View the best growth stocks for 2023 here. Are investors shorting BioNTech? BioNTech saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,660,000 shares, a decline of 18.4% from the October 31st total of 3,260,000 shares. Based on an average daily volume of 636,800 shares, the days-to-cover ratio is currently 4.2 days. Currently, 1.1% of the shares of the stock are sold short. View BioNTech's Short Interest. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our BNTX earnings forecast. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) issued its earnings results on Monday, November, 6th. The company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analysts' expectations of $850.50 million. BioNTech had a trailing twelve-month return on equity of 13.15% and a net margin of 41.09%. The business's revenue for the quarter was down 74.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $7.04 EPS. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB). What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.59%), Primecap Management Co. CA (1.93%), Flossbach Von Storch AG (1.47%), Artisan Partners Limited Partnership (0.31%), Altrinsic Global Advisors LLC (0.29%) and Morgan Stanley (0.24%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More This page (NASDAQ:BNTX) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.